Navigation Links
Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
Date:11/27/2007

29 presentations on ZEVALIN(R) scheduled at American Society of Hematology

(ASH) Annual Meeting

SEATTLE, Nov. 27 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced it intends to utilize the results of the phase III first-line indolent trial of ZEVALIN (Ibritumomab Tiuxetan), known as the FIT trial, for submission to the United States Food and Drug Administration (FDA) for potential approval in the consolidation of first remissions following chemotherapy for patients with follicular non-Hodgkin's lymphoma (NHL). CTI has signed an agreement to acquire the U.S. marketing, sales and development rights to ZEVALIN, however, that acquisition has not yet been completed and remains subject to closing conditions, including obtaining certain third party consents, and until the transaction is closed, ZEVALIN remains a product and trademark of Biogen Idec, Inc. CTI expects the acquisition to close by the end of November and as such is hosting a booth at the ASH meetings. The results of the FIT trial will be presented in an oral session on Monday, December 10 at 3:30 p.m. (Eastern) at the 49th Annual Meeting of the American Society of Hematology (ASH), being held December 8-11, 2007 in Atlanta.

Bayer Schering recently announced it had submitted the FIT results to the EMEA for consideration for a new indication for the product in the European Union (EU). "With our commercial leadership now on board we look forward to the prospects of working closely with Bayer-Schering in providing the support for the Zevalin brand that this important therapeutic deserves," said James A. Bianco, M.D., President and CEO of CTI.

Other presentations at ASH, includ
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) to Present at BIO Investor Forum
3. Horizon Therapeutics, Inc. Scheduled to Present at Upcoming BioPartnering Europe Meeting
4. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
5. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
6. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
9. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
10. Health Plans Increase Use of Health Incentives
11. Area Health Care Providers Announce Plans to Integrate Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Dr. Connie Casad has announced that she will be relocating ... 12200 Park Central Drive, Suite 200, Dallas, Texas 75251 on ... Aesthetics, Optimal Health and Wellness, her gynecology practice and concierge ... said, “The patients’ comfort and satisfaction are our primary goal. ... always feel like their needs are valued and recognized by ...
(Date:9/23/2014)... rapidly developing, bringing with its advances promises of ... and treatment interventions. Genetic tests are already ... and hepatitis c virus (HPC), and emerging research ... screen for an individual,s susceptibility to addiction to ... , While there appear to be many benefits ...
(Date:9/23/2014)... News) -- Few children who take medication for ... the rates vary six-fold across counties in the ... alone can manage symptoms for many children with ... receive behavioral therapy (psychotherapy), the Rand Corp. researchers ... than 1,500 counties across the United States that ...
(Date:9/23/2014)... Both patients and healthcare professionals believe diagnosis of ... greatly outweighs the potential disadvantages of subsequent radiologic ... according to a new study published in the ... , Diagnostic tests used for cancer screening programs ... for colorectal cancer with CT colonography, abdominal and ...
(Date:9/23/2014)... Boston, MA (PRWEB) September 23, 2014 ... announced that $50,000 investments each were made to ... the top two health ventures with business solutions to ... , SOURCE is a first-of-its-kind collaboration between The ... Investors' Circle that connects entrepreneurs with the investment ...
Breaking Medicine News(10 mins):Health News:Dr. Connie Casad Moving to New Office Location 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Kids Taking ADHD Drugs Get Little Psychotherapy: Study 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 2Health News:Patients accept false-positives to achieve diagnostic sensitivity 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 2Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 3Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 4Health News:$100,000 Awarded to Rimidi Diabetes and TruClinic for Health Business Solutions that Benefit Patients and Providers 5
... talked about by only 20% of patients , , MONDAY, ... rheumatoid arthritis (RA) may be at increased risk for ... says a U.S. study that included 200 RA patients ... Betsy Sleath, of the University of North Carolina at ...
... Feb. 11 CAQH announced today,that the eligibility ... for Information Exchange (CORE) Phase I rules is ... Panel,s (HITSP) first set,of interoperability standards. These standards ... Mike Leavitt late last month., This recognition ...
... Feb. 11 The Employer Support of the ... Alliance to,its list of companies that provide extra-ordinary ... Reserves., National ESGR Executive Director Dr. Gordon ... gathering of the company,s leadership Sunday,in Westlake Village. ...
... Chesapeake Corporation,(NYSE: CSK ), a leading international ... supplier of printed pharmaceutical,leaflets in North America, today ... on Long Island, N.Y., and relocating,from its current ... "Our business has grown substantially since we moved ...
... at Childrens Hospital of Pittsburgh of UPMC have identified a ... the development of a vaccine to prevent and new therapies ... Research led by Jay K. Kolls, MD, chief of the ... identified for the first time the importance of a protein ...
... MINNEAPOLIS, Feb. 11 Uroplasty, Inc. (Amex:,UPI), ... and markets,innovative proprietary products for the treatment ... PC Neuromodulation System, its,proprietary, minimally invasive nerve ... bladder (OAB) symptoms, will be,featured in three ...
Cached Medicine News:Health News:Depression Rarely Discussed With RA Patients 2Health News:CAQH Core Rules Final Component of HITSP Interoperability Standards Formally Recognized By HHS Sec. Leavitt 2Health News:CAQH Core Rules Final Component of HITSP Interoperability Standards Formally Recognized By HHS Sec. Leavitt 3Health News:TriWest Named 'Top-Level' Employer of Guard, Reserve Troops 2Health News:Chesapeake to Expand and Relocate North American Pharmaceutical Packaging Operation 2Health News:Children's Hospital scientists identify possible target for prevention and treatment of pneumonia 2Health News:Studies on Urgent(R) PC to be Presented at the 2008 Society of Urologic Nurses and Associates Annual Symposium 2
(Date:9/23/2014)... , Sept. 23, 2014 Research ... the "Physician Office Laboratory Markets, 3rd Edition" ... This report, Physician Office Laboratory Markets is Kalorama,s ... IVD industry. Physician office laboratories are diverse in ... perform reimbursable, in-office pregnancy and glucose tests. Some ...
(Date:9/23/2014)... DUBLIN , September 23, 2014 /PRNewswire/ ... ) has announced the addition of the  ...  report to their offering.  ... injectable drug delivery market holds significant potential ... with vials and painful needles to the ...
(Date:9/23/2014)... -- SiteOne Therapeutics Inc. today announced the completion of its ... Management and Biobrit LLC, with additional investors Mission Bay ... financing positions SiteOne to advance its oral Na V ... its technology platform for long-acting local analgesics, pain diagnostics ... the financing, Lowell Sears (Sears Capital Management) ...
Breaking Medicine Technology:Physician Office Laboratory Markets, 3rd Edition 2Physician Office Laboratory Markets, 3rd Edition 3Large Volume Wearable Injectors - 2nd Edition 2Large Volume Wearable Injectors - 2nd Edition 3Large Volume Wearable Injectors - 2nd Edition 4Large Volume Wearable Injectors - 2nd Edition 5SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 2SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant 3
... 3 Australian researchers have developed gene expression ... colorectal growths from non-cancerous controls. , , ... conference in Chicago, the preliminary findings are the ... Flinders University and Australian healthcare company, Clinical Genomics ...
... Day 3 And All Subsequent Study Visits - , ... Pharma Co., Ltd., (DSP) announced today that positive results from ... of patients with schizophrenia have been published in The ... placebo-controlled trial, involving 180 patients with acute schizophrenia, evaluated a ...
Cached Medicine Technology:Advance in Bowel Cancer Test Research 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 2Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 3Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry 4
0.5mm "K" hook. Rounded knurled handle; shaft angled 11mm from tip; overall length 120mm, in Titanium....
Lightly Curved-Blunt Tips Rounded Blades; 1mm Eye in Blades; 27mm from mid screw to tip. Matte finish; Stainless Steel, overall length 120mm...
... Perfusion Catheter is indicated for ... portion of a coronary artery ... the purpose of improving myocardial ... are also designed to provide ...
... The eSpeed C300 uses its hallmark 50 and ... techniques. New MultiPhase scan protocols and proprietary ... C300s four beam targets and two x-ray detector ... arteries and analyze myocardial perfusion and wall motion. ...
Medicine Products: